Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Roche : Aspen welcomes decision to drop price probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:52pm CET

Aspen yesterday welcomed the Competition Commission`s decision to drop the excessive pricing investigations against it and agent Equity.

The commission yesterday halted its probe, charging that it could not sustain a case of excessive pricing against it.

However, it said its investigations into Roche, US-based technology company Genentech and Pfizer were continuing. Aspen chief executive Stephen Saad said the decision to investigate was expeditious and co-operative.

The decision follows the commissions initiation of investigations against Aspen, Roche, Genentech, Pfizer and Equity in June for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in South Africa. When the commission announced the probe, Commissioner Tembinkosi Bonakele said the anti-graft agency had identified the health-care sector, and in particular pharmaceuticals, as a priority sector for its enforcement efforts due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable.

Yesterday, the commission said the Aspen probe revealed that the revenue attributable to Myleran, Alkeran and Leukeran was low as the products were at the end of their lifespans. In respect of Equity, the investigation revealed that the drug, Xalkori Crizotinib, is not yet registered in South Africa. It was imported once with the permission of the Medicines Control Council. The high price charged by Equity was as a result of high cost incurred in importing the product from Germany, the commission said.

(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
03:06a IONIS PHARMACEUTICALS : gets $45M after Huntington's drug passes early test
12/11 ROCHE : Histone modifier is implicated in epithelial-mesenchymal transition
12/11 CHUGAI PHARMACEUTICAL : Emicizumab Every Four Weeks Showed Positive Interim Resu..
12/11 ROCHE : Genentech's HEMLIBRA Every Four Weeks Controlled Bleeds in Phase III Stu..
12/11 ROCHE : Genentech - Phase III IMpower150 Study Showed Tecentriq and Avastin Plus..
12/11 Merck raises stakes in lung cancer as rivals close in
12/11 ROCHE : Phase III IMmotion151 study showed Roche's Tecentriq (atezolizumab) and ..
12/11 ROCHE : Phase II data showed Roche's investigational polatuzumab vedotin plus be..
12/11 ROCHE : Meeting access challenges with adaptive trial designs
12/11DJROCHE : Reports Positive Results From IMmotion151 Kidney Cancer Trial
More news
News from SeekingAlpha
12/11 Roche Delivers Some Clinical Wins, But Skepticism Remains Largely Intact
12/11 Tecentriq/Avastin combo beats Pfizer's Sutent in late-stage kidney cancer stu..
12/11 Ionis Pharmaceuticals licenses IONIS-HTT Rx to Roche following successful Pha..
12/08 Akari's Coversin successful in mid-stage PNH study
12/08 Roche Holding AG (RHHBY) Investor Presentation - Slideshow
Financials ( CHF)
Sales 2017 53 500 M
EBIT 2017 18 164 M
Net income 2017 10 965 M
Debt 2017 10 098 M
Yield 2017 3,58%
P/E ratio 2017 18,09
P/E ratio 2018 16,59
EV / Sales 2017 4,07x
EV / Sales 2018 3,83x
Capitalization 208 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 274  CHF
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.3.40%208 877
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
MERCK AND COMPANY-7.68%151 559
AMGEN18.98%127 332